Skip to main content

Peer Review reports

From: Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts

Original Submission
6 Oct 2004 Submitted Original manuscript
29 Nov 2004 Reviewed Reviewer Report - Avi Ashkenazi
5 Dec 2004 Reviewed Reviewer Report - Alexandru Almasan
9 Dec 2004 Author responded Author comments - Christina Voelkel-Johnson
Resubmission - Version 2
9 Dec 2004 Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
1 Jan 2005 Reviewed Reviewer Report - Avi Ashkenazi
5 Jan 2005 Reviewed Reviewer Report - Alexandru Almasan
6 Jan 2005 Author responded Author comments - Christina Voelkel-Johnson
Resubmission - Version 4
6 Jan 2005 Submitted Manuscript version 4
Publishing
7 Jan 2005 Editorially accepted
7 Jan 2005 Article published 10.1186/1471-2407-5-2

You can find further information about peer review here.

Back to article page